In homogeneous catalysis, the catalyst is in the same phase as the reactant. The number of collisions between reactants and catalyst is at a maximum.In a patent, 3889-13-2, name is 5-Nitro-2,3-dihydro-1,3-benzoxazol-2-one, introducing its new discovery. Quality Control of 5-Nitro-2,3-dihydro-1,3-benzoxazol-2-one
SUBSTITUTED NITROGEN CONTAINING COMPOUNDS
Disclosed are compounds of Formula (I): or a salt thereof, Formula (II) wherein R1 is: or; each W is independently NR1b or O; Z is a bond or CHR1d; and R1, R2, Rd, R3a, R3b, L1, B, V, Y, and n are defined herein. Also disclosed are methods of using such compounds as inhibitors of ROMK, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating cardiovascular diseases.
We¡¯ll also look at important developments in the pharmaceutical industry because understanding organic chemistry is important in understanding health, medicine, the role of 3889-13-2, and how the biochemistry of the body works.Quality Control of 5-Nitro-2,3-dihydro-1,3-benzoxazol-2-one
Reference£º
Benzoxazole – Wikipedia,
Benzoxazole | C7H5NO – PubChem